Evidence variable handling not specified
Race/Ethnicity:: Black/Sub Saharan African
Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
Research Study from which this is a baseline group
Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
Age, Continuous for QUARTET LDQT at baseline in NCT03640312
Age, Continuous for Candesartan at baseline in NCT03640312
Age, Continuous for Total at baseline in NCT03640312
Sex: Female, Male for QUARTET LDQT at baseline in NCT03640312
Sex: Female, Male for Candesartan at baseline in NCT03640312
Sex: Female, Male for Total at baseline in NCT03640312
Race/Ethnicity, Customized for QUARTET LDQT at baseline in NCT03640312
Race/Ethnicity, Customized for Candesartan at baseline in NCT03640312
Race/Ethnicity, Customized for Total at baseline in NCT03640312
Body Mass Index, kg/m^2 for QUARTET LDQT at baseline in NCT03640312
Body Mass Index, kg/m^2 for Candesartan at baseline in NCT03640312
Body Mass Index, kg/m^2 for Total at baseline in NCT03640312
Heart rate, beats per minute for QUARTET LDQT at baseline in NCT03640312
Heart rate, beats per minute for Candesartan at baseline in NCT03640312
Heart rate, beats per minute for Total at baseline in NCT03640312
History of diabetes, n (%) for QUARTET LDQT at baseline in NCT03640312
History of diabetes, n (%) for Candesartan at baseline in NCT03640312
History of diabetes, n (%) for Total at baseline in NCT03640312
History of smoking, n (%) for QUARTET LDQT at baseline in NCT03640312
History of smoking, n (%) for Candesartan at baseline in NCT03640312
History of smoking, n (%) for Total at baseline in NCT03640312
History of depression, n (%) for QUARTET LDQT at baseline in NCT03640312
History of depression, n (%) for Candesartan at baseline in NCT03640312
History of depression, n (%) for Total at baseline in NCT03640312
Weekly alcohol use, n (%) for QUARTET LDQT at baseline in NCT03640312
Weekly alcohol use, n (%) for Candesartan at baseline in NCT03640312
Weekly alcohol use, n (%) for Total at baseline in NCT03640312
Systolic Blood Pressure, mm Hg for QUARTET LDQT at baseline in NCT03640312
Systolic Blood Pressure, mm Hg for Candesartan at baseline in NCT03640312
Systolic Blood Pressure, mm Hg for Total at baseline in NCT03640312
Diastolic Blood Pressure, mm Hg for QUARTET LDQT at baseline in NCT03640312
Diastolic Blood Pressure, mm Hg for Candesartan at baseline in NCT03640312
Diastolic Blood Pressure, mm Hg for Total at baseline in NCT03640312
Baseline Characteristics Report for QUARTET Trial
Baseline Characteristics Report for QUARTET Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370510. Revised 2025-10-11. Available at: https://fevir.net/resources/Composition/370510. Computable resource at: https://fevir.net/resources/Composition/370510#json.
Baseline Characteristics Report for NCT03640312